ArticleClinical and diagnostic laboratory immunology1998
A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses.
Article in Clinical and diagnostic laboratory immunology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 127 citations in OpenAlex.
- Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study.Human vaccines & immunotherapeutics · 2015Trial
- Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation.Clinical and vaccine immunology : CVI · 2007Trial
- Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?Clinical and vaccine immunology : CVI · 2006Trial
- Priming for immunologic memory in adults by meningococcal group C conjugate vaccination.Clinical and vaccine immunology : CVI · 2006Trial
- A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.Infection and immunity · 2002Trial
- Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection.Infection and immunity · 2002Trial
- Importance of complement source in measuring meningococcal bactericidal titers.Clinical and diagnostic laboratory immunology · 2001Trial
- Relationship between serum bactericidal activity and serogroup-specific immunoglobulin G concentration for adults, toddlers, and infants immunized with Neisseria meningitidis serogroup C vaccines.Clinical and diagnostic laboratory immunology · 2000Trial
- Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents.Infection and immunity · 2000Trial
- Hybrid response to SARS-CoV-2 andHuman vaccines & immunotherapeutics · 2024Article
- Assessment of Immunologically Potent Carbohydrates.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Immunological Effects of Dimethyldioctadecylammonium Bromide and Saponin as Adjuvants for Outer Membrane Vesicles fromDiseases (Basel, Switzerland) · 2022Article
- Modified ELISA for antibody avidity evaluation: The need for standardization.Biomedical journal · 2021Review
- Immunogenicity of antigens from outer membrane vesicles ofClinical and experimental vaccine research · 2021Article
- Article
- Cross-reactivity with Brazilian strains ofTherapeutic advances in vaccines and immunotherapy · 2019Article
- Progress toward a group B streptococcal vaccine.Human vaccines & immunotherapeutics · 2018Article
- Article
- Neisseria meningitidis native outer membrane vesicles containing different lipopolysaccharide glycoforms as adjuvants for meningococcal and nonmeningococcal antigens.Clinical and vaccine immunology : CVI · 2014Article
- Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The standardized enzyme-linked immunosorbent assay (ELISA) for measurement of serum immunoglobulin G (IgG) antibody responses to meningococcal C polysaccharide has been modified to employ assay conditions that ensure specificity and favor detection primarily of high-avidity antibodies. The modified and standard assays were used to measure IgG antibody concentrations in sera of toddlers vaccinated with meningococcal polysaccharide vaccine or a meningococcal C conjugate vaccine. The results were compared to the respective complement-mediated bactericidal antibody titers. In sera obtained after one or two doses of vaccine, the correlation coefficients, r, for the results of the standard assay and bactericidal antibody titers were 0.45 and 0.29, compared to 0.85 and 0.87, respectively, for the modified assay. With the standard assay, there were no significant differences between the geometric mean antibody responses of the two vaccine groups. In contrast, with the modified assay, 5- to 20-fold higher postvaccination antibody concentrations were measured in the conjugate than in the polysaccharide group. Importantly, the results of the modified assay, but not the standard ELISA, paralleled the respective geometric mean bactericidal antibody titers. Thus, by employing conditions that favor detection of higher-avidity IgG antibody, the modified ELISA provides results that correlate closely with measurements of antibody functional activity that are thought to be important in protection against meningococcal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.